Prof. Gili Regev Yochai, director of the Infection Prevention and Control Unit at Sheba Hospital, tells Israel Today about the findings of the fourth vaccine trial: "Exceptionally, we publish the results at this stage, before orderly publication and due to the great public interest."
"We are two weeks after 154 people received a fourth dose of Pfizer, and a week after a fourth dose of modern research. Pfizer's dose raised antibodies quite nicely. We saw an increase after a week and another small increase after two weeks to a level a little higher than what we saw after. "The third vaccine. But it's not enough for Omicron."
"The less nice side is that in a test in a group of 6,000 Sheba workers in the serological study we see what values of antibodies people are still infected with. Even the nice value of antibodies that went up, for omicron is not enough.
Prof. Gili Regev-Yohai vaccinates Corona, Photo: Gideon Markovich
Prof. Yochai points out that the fourth booster is probably effective for the Delta and Alpha strains, but for Omicron it is not good enough.
On the vaccine in modernity she said: "It looks very similar to Pfizer's in the first week, but it's early."
She added: "The decision to give the vaccine to vulnerable people was probably the right one. It gives a little advantage but not enough to give the vaccine to the whole population. Should we wait for the development of a vaccine adapted to the micron? Depending on the person's risk level. .
Prof. Regev also notes that, contrary to data from the Ministry of Health, there are currently no severe Delta patients in Sheba: "In the tests we did in Sheba, we see mainly Omicron. We are trying to get final data."
On the decision to shorten the isolation: "Even today we do antigen tests for our employees before release from isolation. The antigen tests that are in dispute - in the first days their sensitivity is low. But repeated tests on Wednesdays and Thursdays are reliable. Let him come out with a mask and with responsibility. "
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us
